Human Cytomegalovirus (HCMV) Immediate-early Enhancer/promoter Specificity During Embryogenesis Defines Target Tissues of Congenital HCMV Infection
Overview
Authors
Affiliations
Congenital human cytomegalovirus (HCMV) infection is a common cause of deafness and neurological disabilities. Many aspects of this prenatal infection, including which cell types are infected and how infection proceeds, are poorly understood. Transcription of HCMV immediate-early (IE) genes is required for expression of all other HCMV genes and is dependent on host cell transcription factors. Cell type-specific differences in levels of IE transcription are believed to underlie differences in infection permissivity. However, DNA transfection experiments have paradoxically suggested that the HCMV major IE enhancer/promoter is a broadly active transcriptional element with little cell type specificity. In contrast, we show here that expression of a lacZ gene driven by the HCMV major IE enhancer/promoter -524 to +13 segment is restricted in transgenic mouse embryos to sites that correlate with known sites of congenital HCMV infection in human fetuses. This finding suggests that the IE enhancer/promoter is a major determinant of HCMV infection sites in humans and that transcription factors responsible for its regulation are cell type-specifically conserved between humans and mice. The lacZ expression patterns of these transgenic embryos yield insight into congenital HCMV pathogenesis by providing a spatiotemporal map of the sets of vascular, neural, and epithelial cells that are likely targets of infection. These transgenic mice may constitute a useful model system for investigating IE enhancer/promoter regulation in vivo and for identifying factors that modulate active and latent HCMV infections in humans.
Viral enhancer mimicry of host innate-immune promoters.
Kropp K, Angulo A, Ghazal P PLoS Pathog. 2014; 10(2):e1003804.
PMID: 24516378 PMC: 3916337. DOI: 10.1371/journal.ppat.1003804.
Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis.
Schleiss M Infect Disord Drug Targets. 2011; 11(5):449-65.
PMID: 21827434 PMC: 3869401. DOI: 10.2174/187152611797636721.
Isern E, Gustems M, Messerle M, Borst E, Ghazal P, Angulo A J Virol. 2010; 85(4):1732-46.
PMID: 21106746 PMC: 3028895. DOI: 10.1128/JVI.01713-10.
Gustems M, Busche A, Messerle M, Ghazal P, Angulo A J Virol. 2008; 82(20):10302-7.
PMID: 18684819 PMC: 2566294. DOI: 10.1128/JVI.01255-08.
Msx2 exerts bone anabolism via canonical Wnt signaling.
Cheng S, Shao J, Cai J, Sierra O, Towler D J Biol Chem. 2008; 283(29):20505-22.
PMID: 18487199 PMC: 2459292. DOI: 10.1074/jbc.M800851200.